Table 1.
Patient demographics | |
---|---|
Participants, n | 13 |
Number of eyes, n | 18 |
Male, n (%) | 11 (85%) |
Right eyes, n (%) | 8 (44%) |
Age (years) | 68 ± 6.6 |
Baseline BCVA, number of letters | 61.5 ± 13.8 |
Baseline CMT (µm) | 433.2 ± 101.4 |
Total previous bevacizumab injections, n | 7 ± 5.6 |
Number bevacizumab injections in preceding 6 months, n | 1.8 ± 1.5 |
Total previous ranibizumab injections, n | 4.3 ± 4.4 |
Number ranibizumab injections in preceding 6 months, n | 1.2 ± 1.5 |
Total intravitreal injections (IVI) pre-switch, n | 11.3 ± 7.2 |
Total IVI previous 6 months, n | 3 |
Follow-up (months) | 22.5 ± 7.9 |
Data expressed as mean ± SD
SD standard deviation, DMO diabetic macular oedema, BCVA best corrected visual acuity, CMT central macular thickness, IVI intravitreal injections